Press Release

Morgan Lewis Advises Metuchen Pharmaceuticals in Merger Agreement with Neurotrope Inc.

May 18, 2020

WASHINGTON, DC, May 18, 2020: Morgan Lewis is representing Metuchen Pharmaceuticals LLC in the company’s definitive agreement to merge with Neurotrope Inc. Under the terms of the agreement, the all-stock transaction will result in a newly formed holding company to be renamed Petros Pharmaceuticals Inc. that will focus on men’s health conditions.

Metuchen is a privately held biopharmaceutical company focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health conditions. Neurotrope is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

Partner Andrew Ray, associate Andrew Arthur, and of counsel Jeffrey Letalien represented Metuchen.

For more, read the joint announcement.